A prospective study of cardiac biomarkers in monitoring cardiac arrhythmia in Non-Hodgkin's lymphoma chemotherapy

Every year, millions of people are treated for non-Hodgkin's lymphoma, a type of cancer that affects the immune system. The standard treatment often involves a powerful combination of drugs known as CHOP, which includes chemotherapy agents designed to kill cancer cells. While this regimen is effective at shrinking tumors, it carries a hidden risk: the drugs can also damage the heart. This damage, known as cardiotoxicity, can lead to serious complications like irregular heartbeats or heart failure. For decades, doctors have relied on ultrasound scans to measure how well the heart pumps blood, a metric called the ejection fraction. However, this method has a blind spot; it often only detects damage after the heart muscle has already begun to weaken, by which time the injury may be harder to reverse. To catch these problems earlier, scientists have turned to blood tests that look for tiny proteins released when heart cells are stressed or injured, hoping to find a warning signal before the heart's pumping ability declines.

In a new study conducted at Fudan University Shanghai Cancer Center, researchers set out to see if monitoring these specific blood proteins could predict heart rhythm problems in patients undergoing CHOP chemotherapy. They followed forty-five adults with non-Hodgkin's lymphoma from the start of their treatment through four cycles of therapy. Before each round of chemotherapy, the team drew blood to measure levels of four different cardiac markers: high-sensitivity troponin T, a protein that signals heart muscle injury; N-terminal pro-B-type natriuretic peptide, which rises when the heart is under strain; soluble growth-stimulated expressed gene 2, a marker linked to heart stress and failure; and heart fatty acid-binding protein, another indicator of cellular damage. At the same time, the patients underwent electrocardiograms to check for irregular heartbeats and echocardiograms to measure heart function. The researchers then split the group into two categories: those who developed an irregular heartbeat during treatment and those who did not.

The results revealed a clear pattern in the blood of patients who experienced heart rhythm issues. In the group that developed arrhythmias, the level of high-sensitivity troponin T began to rise significantly as early as the first cycle of chemotherapy, peaked during the second cycle, and then slowly declined, though it remained higher than in the healthy group. Similarly, the levels of soluble growth-stimulated expressed gene 2 showed a notable jump during the second cycle for these patients. In contrast, the patients who maintained normal heart rhythms showed no such significant spikes in these markers. The study found that the changes in these two specific proteins, when tracked from the start of treatment to the second cycle, were strong predictors of who would develop an irregular heartbeat. When the researchers combined the data from both markers, their ability to predict the problem improved further, correctly identifying the risk in a high percentage of cases.

Interestingly, the study also observed that the heart's pumping strength, measured by the ejection fraction, did not drop significantly until the fourth cycle of treatment, and only in the group that had already developed rhythm problems. This suggests that the blood markers detected the stress on the heart cells long before the heart's overall pumping function began to fail. Other markers, such as the protein linked to heart strain and the fatty acid-binding protein, did not show the same consistent or significant changes between the two groups. The researchers concluded that by watching for early rises in high-sensitivity troponin T and soluble growth-stimulated expressed gene 2, doctors might be able to identify patients at risk of chemotherapy-induced heart rhythm issues much earlier than current methods allow. This early warning could potentially allow for timely adjustments to treatment, helping to protect the heart while still fighting the cancer. The study acknowledges that while these findings are promising, the group of patients was relatively small, and further research with larger numbers is needed to confirm these results and determine how best to use them in everyday medical practice.